Overview Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 Status: Completed Trial end date: 2015-11-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer. Phase: Phase 2 Details Lead Sponsor: Orion Corporation, Orion Pharma